ProBio has both pilot-scale and commercial-scale GMP manufacturing facilities in China for antibody
and protein drugs. Our diversified facilities satisfy the needs of drug substance GMP manufacturing
and aseptic filling at all scales, from IND to commercialization.
ProBio's overall capacity for drug substance manufacturing has exceeded 20,000 liters. Our upstream
production lines are equipped with single-use bioreactors ranging from 50L to 2,000L, allowing us to
meet the manufacturing needs of various projects.
ProBio boasts two fully automated aseptic filling lines for liquid injection, lyophilized injection, prefilled
syringe, and nasal spray filling. All of the core equipment of the two filling lines is from global top-tier
companies, ensuring the delivery of high-quality products.
150+
190+
3
CMC/CMO projects
GMP batches successfully delivered
PCPV projects
*As of Dec.2025
Quality System
Comply with FDA, EMA, and NMPA GMP Regulations
Client
Audits#
240+ client audits, including US & EU clients
Pass EU QP audits 6 times
Regulatory
1 PAI from BPOM (Indonesian food and
Inspection /QP Audits
drug authority)
• On schedule
CAPA Completion
• Drug Manufacturing Certificate
Certificate
issued by NMPA*
# External Audit History of GenScript ProBio (2019.7-2025.12)
* NMPA refers to China’s National Medical Products Administration
1